The Supreme Court temporarily halted a lower-court order that would have required patients to visit a healthcare provider in person to obtain mifepristone, the abortion pill. The decision preserves access to medication abortion by mail while legal challenges continue.
A federal judge had reinstated an FDA requirement mandating in-person visits for mifepristone dispensing, reversing the agency's 2023 decision to allow remote prescribing and mail delivery. The Supreme Court's temporary stay keeps the FDA's telehealth policy in place, at least for now.
The case centers on whether the FDA properly relaxed restrictions on mifepristone distribution during the COVID-19 pandemic and whether those changes should remain permanent. Anti-abortion groups challenged the FDA's authority to modify the drug's Risk Evaluation and Mitigation Strategy (REMS) program, which originally required in-person pickup at certified clinics.
Mifepristone accounts for roughly half of all abortions in the United States. The medication blocks progesterone, triggering miscarriage, and is FDA-approved through 10 weeks of pregnancy. Studies show medication abortion via telehealth is safe and effective when patients have access to follow-up ultrasounds and emergency care.
The temporary court action does not resolve the underlying legal dispute. The Supreme Court will likely face a broader decision about the drug's availability, given the conflicting rulings across lower courts. Different judges have issued contradictory orders about whether states can restrict or ban mifepristone, creating uncertainty for patients and providers.
The ruling affects abortion access in states where medication abortion remains legal. In states with bans or near-total prohibitions, mifepristone is unavailable regardless of court orders. For those with legal access, mail delivery removes barriers for patients in rural areas, those with limited transportation, and those managing time constraints around work or